Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK of SR419 in Healthy Volunteers
NCT04021563Phase 1Completed
- Sponsor
- Shanghai SIMRD Biotechnology Co., Ltd.
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Peripheral neuropathic pain comparing SR419 with Placebo (2 arms). Primary endpoints: Frequency and severity of Adverse Events (AEs), Heart rate changes since baseline and 8 more. Started Jul 2019; status: completed.
02
Drugs
sr419
03
Conditions
Peripheral neuropathic pain
Beyond the preview
Go deeper on NCT04021563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04021563.